Dr Muthiah Sivaramalingam

Dr Muthiah Sivaramalingam has been a Consultant Clinical Oncologist in the United Kingdom for over 13 years. He has been involved in the treatment of patients with different types of cancers with an ever-evolving array of therapeutic modalities in a rapidly changing and exciting field of clinical oncology over the last decade. Dr Sivaramalingam has been involved in the forefront of developments such as IMRT, IGRT and SABR. Unique to the practice in the United Kingdom, as a Clinical Oncologist, he is also experienced in the use of various forms of systemic therapies for treatment of solid tumours including biological agents, targeted agents and more recently immunotherapy in various combinations in this specialty. Dr Muthiah Sivaramalingam is evolved as a leader in a multidisciplinary (MDT) environment. He chaired the weekly Head and Neck cancer Multidisciplinary team (MDT). Dr Sivaramalingam was the lead for Head and Neck Oncology and Tumour site-specific lead for Neuroendocrine Tumour (NET) and Gastrointestinal Tumour (GIST). He was the clinical lead for implementation of IMRT (in 2010) and SABR (2017) in Preston.

I am involved in the implementation of SABR at UHNM currently. I strongly believe in clinical research being the way forward for our future progress in oncology and the self-assessment process of regular auditing aspects of our practice as the cornerstone in providing the best possible care for our patients.